Both the KEYNOTE-061 and KEYNOTE-062 trials achieved good and durable survival benefits in the CPS ≥10 subgroup, suggesting that patients with GC with high levels of PD-L1 expression may better respond to pembrolizumab, further supporting the use of PD-1 antibodies for patients with GC. Here, CD274 is linked to gastric cancer.